Join me!

My team worked in collaboration with Bill Dalton, Kim Blackwell, Atul Butte / India Hook Barnard, Nancy Davidson and Sharon Terry to create a program that touches every component of precision medicine while bringing together all of its key stakeholders.

Leading participating institutions including Stanford Health Care, UCSF, Duke Health, Duke University, Johns Hopkins University, University of Michigan and more will share their learnings and experiences and their successes and challenges, as they make precision medicine the new standard of care for all.

More than 400 speakers, 5 tracks, 60 sessions, and 2,000+ attendees focusing on:

• AI/Machine Learning advancements and applications
• Genomic Medicine in the clinic
• Immunotherapy Advancements
• Next-generation sequencing developments and applications
• The importance of Data Sharing and Data Privacy
• The rise of New Healthcare Models that revamp health care
• And many other relevant sessions on Precision Medicine, including liquid biopsy applications, population genome initiatives, big data analysis, real-world evidence for decision-making, along with the much-discussed and debated CRISPR-Cas9 genome editing tool

My team and collaborators worked diligently to bring you this timely conference. I hope to see you there, maybe we can chat in person.
See a preview of the conference agenda below or just shoot me back an email if you are curious.

Best regards,
Tal Behar
Co-Founder & President

PMWC Silicon Valley – Santa Clara Convention Center – January, 20-23

Celebrating 10 Years of Precision Medicine Innovation

PREVIEW of PMWC PROGRAM:

• Awards ceremony honoring Dr. Carl June (University of Pennsylvania), Dr. Feng Zhang (Broad Institute), Sharon Terry (Genetic Alliance), and George D. Yancopoulos (Regeneron) at the Luminary and Pioneer Award Ceremony on Monday January 20, 2019.
• Exhibition with over 60 emerging and established companies and organizations showcasing their products and services. Find the complete list of exhibiting companies here.

DAY 1:
Immunotherapy

• 12 sessions that discuss novel hematologic cancer immunotherapies, IO collaborative group trials, predictive biomarkers and new therapies, regulating T-cells and their response to cancer, combinations with other modalities, beyond PD-(L)1 blockades, genetically engineered T cell-based therapies, cancer neoantigen vaccines, cell-based immunotherapies, an emerging tool for immune response monitoring, and IO intellectual properties.
• Emerging Therapeutics and Immunotherapy showcase with over 40 companies presenting their latest technologies in cell-based immunotherapies, cancer vaccines, patient selection processes, and more.
• Fireside chat:
  • Carl June (University of Pennsylvania) and Kim Blackwell (Eli Lilly)
• Keynotes: Feng Zhang (Broad Institute) and George D. Yancopoulos (Regeneron)
• Presenters include: Kimberly Blackwell (Lilly), Lawrence Fong (UCSF), David Miklos (Stanford), Charles Perou (GeneCentric Therapeutics), Dan Chen, (IGM Biosciences), Mark Raffeld (NIH), Kara Davis (Stanford University), Andrew Allen (Gritstone Oncology), Catherine Polizzi (Morrison & Foerster), Scott Pruitt (Merck), Theresa LaVallee (Parker Institute), George Karlin-Neumann (Bio-Rad), Kurt A. Schalper (Yale University), Chris Linthwaite (Fluidigm), Silvia Chiara Formenti (Weill Cornell Medicine), Adrian Bot (Kite s Gilead Company), Timothy Looney (Thermo Fisher Scientific), Nicholas Dracopoli (PGDx), Andrea van Elsas (Aduro Biotech), and Carl June (University of Pennsylvania).

DAY 1:
Cancer Centers

• 14 presenters from leading Cancer Centers in the US discuss applying precision oncology through Molecular Tumor Board. They will share their learnings and the resulting added value to their institutions and medical communities, as well as the challenges they have overcome.
• Keynotes: James M. Ford (Stanford)
• Presenters include: Shridar Ganesan (Rutgers Cancer Institute of New Jersey), Boris Pasche (Wake Forest University), Stephen B. Gruber (USC Norris Comprehensive Cancer Center), Lincoln Nadauld (Intermountain Health), Anna Berry (Swedish Cancer Institute), Daniel Catenacci (University of Chicago), Alejandro Sweet-Cordero (UCSF), David Spigel (Sarah Cannon), Sheldon Greenfield (University of California, Irvine), Asaf Rotem (Dana-Farber Cancer Institute).

DAY 1 & 2:
AI and Machine Learning

• 13 sessions that address how AI is applied to drug discovery/ development and data sciences, how it aids clinical decision making, how it is applied to precision imaging for prediction, how it drives clinical trial design and patient selection, what the requirements are for a scalable AI/machine learning systems framework, and an AI/Machine Learning investment perspective.
• AI and Data Science showcases with 50 companies presenting their latest innovations in pre-clinical and clinical drug discovery, patient diagnosis and treatment, and scalable systems frameworks.
• Presenters include: Atul Butte (UCSF), Deborah Schrag (Harvard Medical School), Vijay Pande (Andreessen Horowitz), Daphne Koller (Insitro), Aris Baras (Regneron), Jessica Mega (Verily), George Asimenos (DNAnexus), Richard Wender (American Cancer Society), Michael Pellini (Section 32), Andy Beck (PathAI), David Shaywitz (Takeda Ventures), Lee Pierce (Sirius Computer Solutions), Kim Branson (Genentech), Vipin Gopal (Eli Lilly and Company), Malvina Eydelman (FDA), Michael D. Abramoff (IDx), Lizzie Dorfman (Google AI), Suzanne Belinson (Tempus), John McHutchison (Gilead), Lon Cardon (BioMarin), Kerrie Holley (Optum), Julie Iskow (Medidata), and many more.

DAY 2:
NGS

• 10 sessions that address various aspects of genomic medicine, including population-based biobanking, cancer phenotyping and screening, emerging applications, ethical implications of using whole exome sequencing in prenatal and young children, performing genomics at scale, ensuring access to genetic counseling, and why we need to focus on healthy people as well as sick people in genomic medicine.
• Company showcases with over 60 companies presenting:
  • Clinical & Research Tools with 28 presenters showcasing their latest innovations that represent breakthroughs in genetic health, rare disease, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies that empower rapidly evolving genomic revolution.
• Fireside Chat Francis deSouza (Illumina) & Emily Leproust (Twist Bioscience)
• Presenters Include: Steve Quake (Stanford), Catherine Brownstein (Boston Children Hospital), Hanlee Ji (Stanford), Allison Ballmer (Agilent,) Carlos Bustamante (Stanford University), Jeffrey Edward Miller (Invivoscribe), J. Michael Cherry (Stanford University), Chad Robins, Adaptive Biotechnologies, Brady Davis (DNAnexus), Benedict Paten (UC Santa Cruz), James H. Godsey (Thermo Fisher Scientific), Ted Goldstein (UCSF) and Francis deSouza (Illumina).

DAY 2
NEW MODELS

• 6 sessions that presents new models in health care to improve patient care:
  • Ecosystem of Shared Value
  • New Hospital-administrated Drugs Supply Model
  • New Model For Primary Care
  • New Preventive Care Models
• Fireside Chat: Trent Haywood (Blue Cross Blue Shield Institute) and John Hornberger (Genomic Health)
• Presenters Include: Jennifer Splansky Juster (Collective Impact Forum), Gertjan Bartlema (Celularity), William Dalton (M2Gen), Jenny Isaacson (Pancreatic Cancer Action Network), Dan Liljenquist (Intermountain Healthcare / Civica Rx), Amir Dan Rubin (One Medical), Ralph Snyderman (Duke University), Amy Compton-Phillips (Providence St. Joseph Health), Catherine Reinis Lucey (UCSF), J. Craig Venter (JCVI), Brook Byers (KPCB).

DAY 2 & 3:
Genomic Medicine

• 10 sessions that address various aspects of genomic medicine, including population-based biobanking, cancer phenotyping and screening, emerging applications, ethical implications of using whole exome sequencing in prenatal and young children, performing genomics at scale, ensuring access to genetic counseling, and why we need to focus on healthy people as well as sick people in genomic medicine.
• Company showcases with over 60 companies presenting:
  • The Genomic Profiling Showcase – commercial advancements and innovations in DNA/RNA sequencing (methods and instruments)
  • The Clinical Dx Showcase – commercial advancements in expedited, cost-effective, and accurate clinical diagnostics
  • Liquid biopsy Showcase – commercial advancements and developments of screening minimally-invasive tests for oncology, immunotherapy, and other areas
• Presenters include: Harold Paz (Aetna), Keith Yamamoto (UCSF), Erica Ramos (Geisinger), Randy Scott (Invitae), Nancy Davidson (Fred Hutchinson Cancer Research Center), Shannon McCall (Duke University), Minnie Sarwal (UCSF), Mickey Kertesz (Karius), Joe Zhang (Burning Rock Dx), Jean-Francois Martini (Pfizer), Akhil Saklecha (Cleveland Clinic Ventures), Yuri A. Fesko (Quest Dx), Helmy Eltoukhy (Guardant Health), Richard Schilsky (ASCO), Atul Sharan (CellMaxLife), Gordon Mills (OHSU), Cornelius Boerkoel (Sanford Health), Aleksandar Rajkovic (UCSF Health), Varda Shalev (Maccabi Medical Center, Israel), Gad Rennert, Clalit Health Services, Israel, Hakan Sakul (Pfizer), Ellen Beasley (Genomic Health) and many more.

DAY 3
Patient Data

• 11 sessions on the use of new technologies that provide tremendous benefits for both patients and providers, and how to address the increased risks to  security and privacy of patient data that comes with increased sharing. Special focus will be placed on successful use cases and how to overcome obstacles to patient data sharing.
• Fireside chat:
  • Eric Dishman, NIH & Sharon Terry, Genetic Alliance
• Keynote: Seema Verma, CMS
• Presenters include: Jamie Ferguson (Kaiser Permanente), Michael Halaas (Stanford School of Medicine), Tom Insel (MindStrong), Mitch Lunn (UCSF), Andreas Kogelnik (Open Medicine Institute), William Dalton (M2Gen), Bastian Greshake Tzovaras (Open Humans), Jason Bobe (Icahn Institute), Dawn Barry (LunaDNA), George Komatsoulis (CancerLinQ), Patricia Goede (XIFIN), Julie Ramage, (Pfizer), Rebecca Owens, TapRooT, Deven McGraw (Ciitizen) and more.

FULL PROGRAM LINK

2018 has clearly been a year when significant opportunities intersected with strong partnerships to yield advancements. In particular, the clinical advancements that were realized are a testimony to stakeholders working together to deliver on promises affecting major aspects of precision medicine. These include improving how healthcare is executed, how innovation is helping physicians better diagnose and treat patients, and how drug discovery is being conducted to deliver more efficient translational success.

Be it through AI/machine learning, blockchain technology, CRISPR-Cas9, liquid biopsy, NGS, or cancer immunotherapy, the emerging opportunities and early resulting applications are tremendous, we have:

• established rare disease diagnosis
• expedited newborn sick children screening
• launched large scale population studies
• transitioned DNA sequencing to become routine clinical care
• translated immunotherapy discoveries into new therapeutics that, in certain cancer scenarios, are already becoming the new standard of care
• and on the regulatory side, the FDA has finalized guidance to accelerate the development of reliable,beneficial NGS-based tests

Quick Note: Access Discounted Jan. 20-23 Tickets Here by 12/31 – and visit all the facets of Precision Medicine. The overarching result is that , and this is raising our expectations for even more highly impactful developments in 2019.precision medicine is now part of the common vocabulary in healthcare

• Genomic Medicine has reached milestones that, until recently, seemed out of reach: Thermo Fisher Scientific, for example, received FDA approval for the first NGS-based companion Dx (Oncomine DX Target Test); 23andMe achieved the go-ahead to offer a health product DNA-test; AstraZeneca’s PARP inhibitor Lynparza was approved for advanced ovarian cancer and metastatic breast cancer; Stanford researches eliminated all traces of cancer, including distant metastasis, by activating T-cells in mice using a cancer vaccine; the Genetic Counseling Medicare bill was introduced.
• Scientists behind game-changing cancer immunotherapies won Nobel Prize in Medicine. The work of the winners, American James Allison (PMWC Award Honoree) and Japanese Tasuku Honjo led to the creation of a multibillion-dollar market for new cancer medicines.
• AI/Machine Learning continues to change healthcare. The FDA approved in April the first AI-powered diagnostic device to detect certain diabetes-related eye problems that don’t need a doctor’s help.
• Innovative Care Models are new catalysts to transforming healthcare.Amazon, Berkshire Hathaway and JP Morgan Chase are teaming up to form an independent healthcare company for their employees. CVS and Aetna are merging, while Walgreens and LabCorp are partnering.
• Major acquisitions occurred: Flatiron Health and Foundation Medicine were both acquired by Roche, Genohm and ACEA Biosciences by Agilent, Counsyl by Myriad, and Illumina is in the process of acquiring Pacific Biosciences. All will certainly impact the path to a more established approach of expedited, accurate clinical testing and decision-making.
• Population studies have gotten bigger: The “Genomics England” initiative reached 100K participants, the “All of Us Research Program” launched, and is inviting all Americans to join its program, the NHS will start screening all cancer patients for mutations, and Finland’s “FinnGen” project aims to match genome information with over 500K blood samples, just to name a few.
• Other newsworthy events of this year: 23andMe is sharing its 5 million client’s genetic data with drug giant GSK, Oxford Nanopore Technologies mapped the most complete human genome using its MinIon device, and some fed-up hospitals are creating a non-profit generic drug company, Civica Rx, to get some control over the drug supply for patients.

Hear from nearly every one of these organizations at the Precision Medicine World Conference (PMWC), January 20-23rd – See the topics that are at the forefront & who is leading the discussions – PROGRAM.

These developments, while exciting, come with their own consequences and will undoubtedly impact how genomics studies are conducted, how doctors and patients are educated, and will highlight an even bigger need for clarification through regulatory guidelines, and for changes in reimbursement policies.

Be among the first to hear where the field is moving, what  will look like, and how it will . PMWC, January 20-23 has secured a great lineup of 400 speakers and representatives from CMS (Seema Verma), UPenn (Carl June), MIT/Broad Institute (Feng Zhang), Illumina (Francis de Souza), Regeneron (George Yancopoulos), NIH (Eric Dishman), UCSF, Stanford, Google AI, Myriad, Pacific Biosciences, GSK, Thermo Fisher Scientific, Roche, and many more.the next phaseimpact you and your business or career.

“Not only do I see this as risky, but I am also deeply concerned about the lack of transparency surrounding this trial. All medical advances, gene editing or otherwise and particularly those that impact vulnerable populations, should be cautiously and thoughtfully tested, discussed openly with patients, physicians, scientists, and other community members, and implemented in an equitable way.”

Feng Zhang, Broad Institute – Genome editing tool pioneer for use in eukaryotic cells from natural microbial CRISPR-Cas9 systems | Luminary Awardee and PMWC 2019 SV